Reimbursement for telemonitoring of oncology patients: the time has come
After years of pilot projects and scientific research, the moment has finally arrived: as of 1 January 2026, NIHDI reimbursement is available for telemonitoring of oncology patients. The official circular (OMZ. ZH. 2026/04) was published on 2 February 2026.
As the first party in Belgium to submit the reimbursement dossier for oncological telemonitoring to NIHDI, we at Remecare are particularly pleased to share this news. In this blog, we provide an overview of what this reimbursement entails, the applicable conditions, and how Remecare can support hospitals with implementation.
Why telemonitoring in oncology?
The results of telemonitoring for oncology patients are compelling:
• Earlier detection of toxicities and side effects during oncological treatments,
• Maintaining optimal dose intensity and extending treatment duration,
• Better quality of life for the patient,
• Reduced workload for healthcare staff.
In short, integrating telemonitoring into the oncological care pathway offers significant added value for both care quality and efficiency.
What does the reimbursement entail?
Two specific lump-sum payments have been established:
• Onboarding fee (1st month): €84.89, covering the first month of monitoring, including explaining the application to the patient and guiding them through its use. Once per patient per two calendar years.
• Follow-up fee (months 2 to 5): €59.89 per month, covering alert follow-up, answering questions, and guidance. Maximum four times per patient per two calendar years.
Hospitals can start immediately and will be reimbursed as soon as the amendment clause is published in the Belgian Official Gazette, without any further administrative formalities.
Who is eligible?
The reimbursement applies to patients who:
• Are treated with one or more medicines from reimbursement category A, registered under ATC code L01F, as part of an antitumoral treatment, and
• Do not qualify for the "basic oncological care" lump sum.
Composition of the monitoring team
The monitoring team consists of at least:
• A medical oncologist or haematologist, with overall responsibility for the monitoring,
• An oncology nurse (min. 0.5 FTE per 100 patients), responsible for daily alert follow-up and patient contact.
The team works closely with the general practitioner and home nurse to ensure optimal care and coordination in the home setting.
From pilot project to reimbursement: the road we travelled
Remecare is at the origin of this story. For over six years, we have been working with oncological centres such as AZ Maria Middelares Ghent, UZA, CHU UCL Namur (Godinne and Namur) and Grand Hôpital de Charleroi on the development and validation of oncological telemonitoring.
Thanks to Remecare, we can transform unexpected tasks into work that is easier to plan, creating a greater sense of control and less stress for the oncology teamduring cancer treatment, while simultaneously fostering a greater sense of safety and trust in the patient. - Dr. Vuylsteke, AZ Maria Middelares, Ghent
This years-long experience formed the basis for the reimbursement dossier that we were the first party in Belgium to submit, and which has now been officially approved.
After heart failure, now oncology
This is not the first time Remecare has walked this path. Since 1 January 2025, reimbursement has also been available for telemonitoring in heart failure, where we now support 25 Belgian hospitals. The lessons we learned there, from implementation to daily use, are now also being applied in oncology.
How can Remecare support your hospital?
After many pilot projects, we understand the challenges of oncological telemonitoring like no other. That is why we developed a solution that is both hospital- and patient-friendly:
• Patient-friendly: Simple app with guidance on registering symptoms and side effects, available on iOS, Android and via web browser.
• Smart triage: No data overload; Remecare automatically detects patients who need attention, with different alert severity levels.
• Automated next steps: Our validated algorithms always suggest the optimal next step for the patient and the care team members.
• EHR integration: Seamless integration with your electronic health record.
With Remecare, you set up an efficient oncological telemonitoring care pathway that fully complies with all conditions from the circular and the Royal Decree of 27 March 2025.
Want to know how your hospital can start with oncological telemonitoring? Get in touch: www.remecare.eu/contact
